Wenke Hwang

Wenke Hwang

Auto-generated profile, based on publicly available information

Wenke Hwang

Affiliation Department of Public Health Sciences, Penn State University College of Medicine, Hershey, Pennsylvania, United States of America

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
GGGregory Gorman
Gregory Gorman
SFSusan Furth
Susan Furth
WHWenke Hwang
Wenke Hwang
RPRulan Parekh
Rulan Parekh
BABrad Astor
Brad Astor
ANAlicia Neu
Alicia Neu

4 November 2014 in The Journal of Rural Health
Verified
Journal Article
Closed access
PDF file
FCFabian Camacho
Fabian Camacho
WHWenke Hwang
Wenke Hwang
TKTeresa Kern
Teresa Kern
RARoger Anderson
Roger Anderson

21 October 2024 in Journal of Diabetes
Verified
Journal Article
Open access
HHHaowen Hsu
Haowen Hsu
PKPaul Thomas Kocis
Paul Thomas Kocis
APAriana Pichardo‐Lowden
Ariana Pichardo‐Lowden
WHWenke Hwang
Wenke Hwang
Background: Cardiovascular diseases are a common cause of death among patients with type 2 diabetes (T2DM). Major adverse cardiovascular event (MACE) risks can be significantly reduced under adequate glycemic control (GC). This study aims to identify factors that influence MACE risk among patients with T2DM, including Hemoglobin A1c variability score (HVS) and early use of MACE‐preventive glucose‐lowering medications (GLMs).Methods: We conducted a longitudinal cohort study to retrospectively review electronic health records between 2011 and 2022. Patients with T2DM ≥18 years without previous stroke or acute myocardial infarction (AMI) were included. Cox regression was utilized to investigate MACE risk factors and compare MACE risk reduction associated with early use of MACE‐preventive GLMs.Results: A total of 19 685 subjects were included, with 5431 having MACE, including 4453 strokes, 977 AMI, and 1 death. There were 11 123 subjects with good baseline GC. Subjects with good baseline GC had 0.837 (confidence interval [CI]: 0.782–0.895) times lower MACE risk than their counterpart. Subjects with a single MACE‐preventive GLM at baseline with continuous use >365 days showed a decreased MACE hazard ratio (0.681; CI: 0.635–0.731). Among all MACE‐preventive GLMs, semaglutide provided a more significant MACE‐preventive effect.Conclusions: This study identified that GLM, early GC, and HVS are MACE determinants among patients with T2DM. Novel GLM, adequate GC, and reduction of HVS can benefit MACE outcomes. image

17 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAlireza Vafaei Sadr
Alireza Vafaei Sadr
Jiang LiJiang Li
Jiang Li
WHWenke Hwang
Wenke Hwang
MYMohammed Yeasin
Mohammed Yeasin
MWMing Wang
Ming Wang
Vida AbediVida Abedi
Vida Abedi
Missing data in electronic health records (EHRs) poses a significant challenge for analysis. This study introduces Pympute, a comprehensive Python package designed for efficient and robust missing value imputation for EHRs. Pympute’s core algorithm, Flexible, intelligently selects the optimal imputation method for each variable based on its characteristics. Pympute offers a comprehensive suite of functionalities. It benchmarks the performance of ten existing machine learning imputation algorithms against Flexible on real-world EHR datasets containing laboratory measurements. Additionally, Pympute facilitates data simulation, generating realistic datasets mimicking real-world data distributions for controlled evaluation of imputation performance. Finally, Pympute investigates how missingness and skewness, influence the selection of optimal imputation algorithms within the Flexible framework. Our findings validate that Pympute’s Flexible method significantly improves imputation performance compared to the single model approach. Notably, simulating data solely based on covariance does not accurately reflect real-world selection behavior. Furthermore, skewness in the data distribution prompts Flexible to favor nonlinear imputation models. This study highlights the importance of considering data distribution patterns when selecting imputation algorithms. Pympute addresses this challenge by offering a versatile and user-friendly solution for diverse EHR data scenarios.

30 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Vida AbediVida Abedi
Vida Abedi
CLClare Lambert
Clare Lambert
DCDurgesh Chaudhary
Durgesh Chaudhary
EREmily Rieder
Emily Rieder
VAVenkatesh Avula
Venkatesh Avula
Ramin ZandRamin Zand
Ramin Zand
Introduction: The cut-point for defining the age of young ischemic stroke (IS) is clinically and epidemiologically important, yet it is arbitrary and differs across studies. In this study, we leveraged electronic health records (EHRs) and data science techniques to estimate an optimal cut-point for defining the age of young IS. Methods: Patient-level EHRs were extracted from 13 hospitals in Pennsylvania, and used in two parallel approaches. The first approach included ICD9/10, from IS patients to group comorbidities, and computed similarity scores between every patient pair. We determined the optimal age of young IS by analyzing the trend of patient similarity with respect to their clinical profile for different ages of index IS. The second approach used the IS cohort and control (without IS), and built three sets of machine-learning models—generalized linear regression (GLM), random forest (RF), and XGBoost (XGB)—to classify patients for seventeen age groups. After extracting feature importance from the models, we determined the optimal age of young IS by analyzing the pattern of comorbidity with respect to the age of index IS. Both approaches were completed separately for male and female patients. Results: The stroke cohort contained 7555 ISs, and the control included 31,067 patients. In the first approach, the optimal age of young stroke was 53.7 and 51.0 years in female and male patients, respectively. In the second approach, we created 102 models, based on three algorithms, 17 age brackets, and two sexes. The optimal age was 53 (GLM), 52 (RF), and 54 (XGB) for female, and 52 (GLM and RF) and 53 (RF) for male patients. Different age and sex groups exhibited different comorbidity patterns. Discussion: Using a data-driven approach, we determined the age of young stroke to be 54 years for women and 52 years for men in our mainly rural population, in central Pennsylvania. Future validation studies should include more diverse populations.

23 July 2025 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
JAJonathan Arnold
Jonathan Arnold
DADeeksha Acharya
Deeksha Acharya
HBHetal Boricha
Hetal Boricha
HCHimal Chapagain
Himal Chapagain
AKAleesha Kainat
Aleesha Kainat
KMKathleen M McTigue
Kathleen M McTigue
The value of lipid lowering therapy (LLT) for prevention of atherosclerotic cardiovascular disease (ASCVD) is well understood. American College of Cardiology and American Heart Association guidelines recommend statin therapy for secondary and high-risk primary ASCVD prevention. Prior studies have identified incomplete uptake of these guidelines in specific practice settings or patient populations. Here we characterized real-world LLT prescribing relative to guideline recommendations across seven US health systems. Cross-sectional analyses of records from the PaTH Clinical Research Network focused on three cohorts: adults with ASCVD (ASCVD cohort), those aged 40-75 without ASCVD but with diabetes mellitus (DM cohort), and those not in either prior category but with a history of low-density lipoprotein (LDL-C) >190 mg/dl (LDL-C cohort). We describe patient characteristics, patterns of care, lipid values, and documented LLT within each cohort and variation between health systems. We identified 240,625 patients within the ASCVD cohort (LDL-C mean 86, SD 40 mg/dL), 113,662 patients in the DM cohort (LDL-C mean 93, SD 37 mg/dL), and 11,276 patients in the LDL-C cohort (LDL-C mean 208, SD 33 mg/dL. Among ASCVD cohort members, 37 % achieved the target LDL-C < 70 mg/dL, 62 % were prescribed LLT, 34 % were prescribed guideline-concordant high-intensity statin therapy. In the DM cohort, 27 % had LDL-C < 70 mg/dl, 54 % were on statin therapy, 19 % on high-intensity statin therapy. In the LDL-C cohort, 97 % had an LDL-C > 160 mg/dl, 44 % were on statin therapy and 16 % on high-intensity statin therapy. There was significant variability in documented LLT between health systems. In this real-world descriptive study across multiple health systems for patients meeting criteria for secondary or high-risk primary ASCVD prevention, most patients had no documented high-intensity statin prescriptions and did not meet LDL-C targets. There was significant variability in care across health systems. Opportunities remain for improvement in guideline adherence to reduce ASCVD risk.